Ibex Medical Analytics (Ibex), a leader in AI-powered cancer diagnostics, has announced the integration of its advanced AI solutions into routine clinical practice at Institut Curie, one of the world’s most renowned cancer centers. Pathologists at Institut Curie are now leveraging Ibex’s AI tools for prostate cancer diagnosis, enhancing diagnostic accuracy, efficiency, and patient outcomes. Plans are underway to expand the use of Ibex’s applications to other areas in the coming months.
“We are thrilled to incorporate Ibex’s AI technology into our routine practice, building on our successful research collaboration,” said Professor Anne Vincent-Salomon, Head of the Pathology Department at Institut Curie and Professor at the University Paris-Sciences et Lettres. “Accurate diagnostics are crucial for determining the best treatment pathways, and we are committed to equipping our pathologists with state-of-the-art tools to provide the highest quality care for our patients.”
Integrating AI with Digital Pathology
Institut Curie continues to lead in digital pathology adoption, integrating Ibex’s AI tools through their Sectra Digital Pathology Solution. This system ensures a seamless workflow, enabling pathologists to access AI-driven insights directly within their case review process. As one of the first academic laboratories globally to deploy this cutting-edge solution, Institut Curie is setting a benchmark in leveraging AI for clinical applications.
“The implementation of this tool will help our teams save time, increase diagnostic reliability, focus on critical areas, and improve diagnostic precision,” noted Professor Yves Allory, Head of the Pathology Department at Institut Curie’s Saint-Cloud site and Professor at the University of Versailles Saint-Quentin.
A History of Collaborative Innovation
This rollout builds on a longstanding collaboration between Ibex and Institut Curie, which has already resulted in significant advancements in AI-driven cancer diagnostics. Notably, the organizations validated the Ibex Breast solution, a breakthrough published in Nature’s npj Breast Cancer.
“We are honored to see our AI platform adopted in routine practice by such a prestigious institution as Institut Curie,” said Joseph Mossel, CEO of Ibex Medical Analytics. “As a global leader in cancer care and research, Institut Curie continues to pioneer the integration of transformative technologies. This milestone demonstrates the immense potential of AI to revolutionize cancer diagnostics and patient care worldwide.”
With this deployment, Institut Curie reaffirms its commitment to innovation in oncology, harnessing cutting-edge AI solutions to improve outcomes and set new standards in cancer diagnostics.
